Table III.
Genotype distribution and allele frequency analysis of the single nucleotide polymorphisms of multidrug resistance member 1.
| A, T1236C | ||||
|---|---|---|---|---|
| Genotype and alleles | Patients with CRC [n=62; n, (%)] | Healthy controls [n=100; n, (%)] | Fisher's exact P-value | OR (95% CI) |
| Wild-type (TT) | 0 (0) | 0 (0) | 1.000 (Reference) | |
| Heterozygous (TC) | 41 (66.13) | 46 (46) | 1 | N/A |
| Homozygous (CC) | 21 (33.87) | 54 (54) | 1 | N/A |
| Combined (TC+CC) | 62 (100) | 100 (100) | 1 | N/A |
| Dominant (T) | 20 (32.26) | 23 (23) | 1.000 (Reference) | |
| Recessive (C) | 42 (67.74) | 77 (77) | 0.1600 | 0.610 (0.330–1.130) |
| B, G2677T | ||||
| Genotype and alleles | Patients with CRC [n=62; n, (%)] | Healthy controls [n=100; n, (%)] | Fisher's exact P-value | OR (95% CI) |
| Wild-type (GG) | 43 (69.4) | 1 (1) | 1.000 (Reference) | |
| Heterozygous (GT) | 4 (6.5) | 24 (24) | <0.0001 | 0.004 (0.0004–0.040) |
| Homozygous (TT) | 15 (24.1) | 75 (75) | <0.0001 | 0.005 (0.0006–0.040) |
| Combined (GT+TT) | 19 (30) | 99 (99) | <0.0001 | 0.005 (0.0006–0.030) |
| Dominant (G) | 45 (72.58) | 13 (13) | 1.00 (Reference) | |
| Recessive (T) | 17 (27.42) | 87 (87) | 1.6800 | 0.050 (0.020–0.100) |
CRC, colorectal cancer; OR, odds ratio; CI, confidence interval; N/A, not applicable.